HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Judiciary Panel Gets Authority To Craft Patent Legislation

This article was originally published in The Tan Sheet

Executive Summary

The next Congress could streamline House deliberations about patent reform legislation as the full Judiciary Committee assumes jurisdiction over intellectual property issues

You may also be interested in...



Democrats’ Gains Galvanize Leahy’s Push For Patent Reform

Encouraged by election results that increased Democrats' majority in the Senate, Judiciary Committee Chairman Patrick Leahy, D-Vt., will reintroduce his controversial patent reform bill

Hatch IP legislation

Bipartisan sponsors in Congress introduce bills April 18 proposing reforms in patent and intellectual property protection - a top issue for the dietary supplement industry - but say they expect revisions in the face of criticism from the pharmaceutical industry. Sen. Orrin Hatch, R-Utah, says the Patent Reform Act of 2007 (S. 114) has a good chance to pass, but noted at a press conference, "I hope big pharma is not too active" in fighting the legislation. Rep. Howard Berman, D-Calif., is sponsoring a House version of the bill (H.R. 1908). Drug firms oppose provisions to limit awards in infringement suits and allow requests to the Patent and Trademark Office to review a patent throughout its term. The House Subcommittee on Courts, the Internet and Intellectual Property will hold a hearing on the topic April 26. Supplement industry representatives and manufacturers say an inability to obtain patent protection hinders the industry. They suggest collaboration among firms along with trade group input would help reduce occasions of infringement (1"The Tan Sheet, Feb. 5, 2007, p. 8). Similar bills introduced in the past two years failed to pass (2"The Tan Sheet," June 6, 2005, p. 9)...

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel